OptiBiotix Health (LSE:OPTI) Research & Development: £0.00 Mil (TTM As of Dec. 2025)


What is OptiBiotix Health Research & Development?

OptiBiotix Health LSE:OPTI Research & Development is £0.00 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. OptiBiotix Health's Research & Development for the six months ended in Dec. 2025 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was £0.00 Mil.

OptiBiotix Health  (LSE:OPTI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

OptiBiotix Health Research & Development Related Terms

OptiBiotix Health Research & Development Historical Data

* Premium members only.

The historical data trend for OptiBiotix Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OptiBiotix Health Research & Development Chart

OptiBiotix Health Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.07 0.22 0.29 0.32

OptiBiotix Health Semi-Annual Data
Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OptiBiotix Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.00 Mil mean?
OptiBiotix Health (LSE:OPTI) has a Research & Development of £0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on OptiBiotix Health and its competitors.
Is OptiBiotix Health's Research & Development too high?
OptiBiotix Health's current Research & Development is £0.00 Mil.
How does OptiBiotix Health's Research & Development compare to VRTX and REGN?
OptiBiotix Health's Research & Development of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on OptiBiotix Health and its competitors. OptiBiotix Health's current Research & Development is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptiBiotix Health stock overvalued right now?
Based on GuruFocus' analysis, OptiBiotix Health (LSE:OPTI) is currently considered Possible Value Trap. The stock's GF Value™ is £0.30, compared to a current price of £0.06 — trading 78.8% below its estimated fair value. The current Research & Development is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For OptiBiotix Health (LSE:OPTI), the current Research & Development is £0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OptiBiotix Health Business Description

Address Innovation Centre, Innovation Way, Heslington, York, GBR, YO10 5DG
OptiBiotix Health PLC principal activity is that of identifying and developing microbial strains, compounds, and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. It is a life sciences business focused on the development of products which reduce hunger and food cravings, enhance the gut microbiome, and provide a healthy substitute for sugar. Its product portfolio includes First-generation products- SlimBiome, WellBiome; and Second-generation solutions- SweetBiotix, Microbiome Modulators. The group has one class of business. It has presence in United Kingdom, United States, India China, and Rest of world. The company generates majority of revenue from United States.